Navigation Links
BioCryst Clarifies Government Declaration Regarding Peramivir
Date:10/2/2009

urther condition, reduce or eliminate future funding of the peramivir program; that ongoing peramivir clinical trials or our peramivir program in general may not be successful; that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates; that our product candidates may not receive required regulatory clearances from the FDA; that ongoing and future pre-clinical and clinical development may not have positive results; that we or our licensees may not be able to continue future development of our current and future development programs; that our development programs and partnerships may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates; that our actual cash burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, most recent Registration Statement on Form S-3 (filed November 28, 2008), Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

SOURCE BioCryst Pharmaceuticals, Inc.


'/>"/>
SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioCryst Provides Update Regarding Peramivir for Influenza
2. BioCryst Pharmaceuticals Reports Positive Results of Shionogi & Co. Sponsored Phase 3 Studies of i.v. Peramivir for Influenza
3. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
4. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
5. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
6. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
7. BioCryst Updates Peramivir Clinical Development Plan
8. BioCryst Provides Forodesine HCl Update
9. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
10. Mayo Clinic Clarifies Diagnosis and Treatment for Rare, Serious Blood Vessel Disease of Brain and Spinal Cord
11. Southern Research to Play Key Role in the Federal Governments Search for New Cancer Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Quest Diagnostics (NYSE: DGX ), the world,s ... its Board of Directors has elected Jeffrey M. Leiden, ... 2014. Including Dr. Leiden, the Board has 11 members. ... CEO of Vertex Pharmaceuticals.   Dr. Leiden has more ... the pharmaceutical and biotechnology industries as well as clinical ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... , Oct. 22, 2014   Reproductive Medicine ... leader in the field of infertility, presents new ... embryonic screening. The research abstract, released during the ... Medicine (ASRM) meeting in Honolulu, Hawaii ... single gene defect (SGD) pre-implantation genetic diagnosis (PGD). ...
Breaking Medicine Technology:Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... EAST HANOVER, N.J., Aug. 27 The US Food ... tablets, a single-pill for the treatment of high blood ... (aliskiren), with the widely used calcium channel blocker amlodipine. ... are likely to need multiple drugs to achieve their ...
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ... data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += key ...
Cached Medicine Technology:Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 3Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 4Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 5Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 6Novartis receives FDA approval of Tekamlo™, a single-pill combination of aliskiren and amlodipine to treat high blood pressure 7STALLERGENES: Excellent 1st Half-Year 2010 Performance 2STALLERGENES: Excellent 1st Half-Year 2010 Performance 3STALLERGENES: Excellent 1st Half-Year 2010 Performance 4STALLERGENES: Excellent 1st Half-Year 2010 Performance 5STALLERGENES: Excellent 1st Half-Year 2010 Performance 6STALLERGENES: Excellent 1st Half-Year 2010 Performance 7
(Date:10/25/2014)... Barbara, CA (PRWEB) October 25, 2014 ... charity's annual President’s Circle Reception on Monday at the ... FSA’s accomplishments and hear from guest speaker Dr. Winifred ... digital worlds. , Dr. Lender, a Santa Barbara psychologist, ... the challenges and benefits of living in the digital ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 TASC ... medical and other benefits account management services, announces ... help employers save on taxes, reduce administrative workload, ... provide tax savings and the efficient handling of ... the Suite that best meets their goals and ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 ... Molecular Diagnostics Industry, 2009-2019 is a professional ... Chinese Molecular Diagnostics industry. The report firstly ... including its classification, application and manufacturing technology. ... top manufacturers of Molecular Diagnostics listing their ...
(Date:10/25/2014)... Homeowners that are wondering how they can ... no more. Clean Crawls gives 5 signs of ... when it comes to insulation in their recently released ... by Clean Crawls, can cause problems throughout your entire ... has deteriorated, become damp, or been infested with pests ...
(Date:10/25/2014)... October 25, 2014 Mesothelioma researchers are ... to receive pemetrexed (Alimta), after his combination drug therapy ... full story , just posted on the Surviving Mesothelioma ... Tokushukai Medical Center in Japan suggests that “maintenance therapy” ... patients who cannot tolerate higher doses of cisplatin. ...
Breaking Medicine News(10 mins):Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 2Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 3Health News:Finding Balance between the Real & Digital World Topic of Family Service Agency Reception 4Health News:TASC’s New Suites Offer Tax Savings and Protection 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 2Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 3Health News:Global and China Molecular Diagnostics Industry Analysis to 2019 is Now Available at RnRMarketResearch.com 4Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2
... Balehonnur-based Central Coffee Research Institute (CCRI) has said that it ... in December 2007 . ,After 21 years of ... December 15. The yet-to-be named hybrid, hi-yielding arabica variety is ... resistant to the widely prevalent white stem borer. ...
... again when she was pictured with baby bump . ... Travolta starrer Hairspray dressed in a figure-hugging black dress that ... ,Holmes sparked off rumours that she and hubby ... spotted with bump while visiting new best friends David and ...
... the entire Test series against India with a hernia injury.Harmison ... to six weeks, reports BBC . ,England coach ... back and now it's all about getting the operation done ... Chris Tremlett are vying for the third seamer's spot for ...
... government was not averse to inviting the World Health Organisation ... fever in the state that has claimed 173 lives this ... arrived in the state since the outbreak of the fever, ... the fever as chikunguniya and nothing else, we have no ...
... dysfunction can overcome their problem by taking part in ... ,The study also suggests that supplementing sildenafil, ... other names, to group therapy can make the treatment ... sexual function relies on the coordination of psychological, endocrine, ...
... The Punjab University has reserved seats for students suffering from ... ,The University has reserved one seat for each of ... AIDS or suffering from cancer. ,However, the university ... sufficient for the time being, since it do not expects ...
Cached Medicine News:Health News:Harmison Ruled Out Off Test Series Due to Hernia 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: